linjc16/ctgov huggingface dataset:
COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital

Study Overview
=================
Brief Summary
-----------------
We aimed to describe the frequency; presentations, predictors, in-hospital outcome of mucormycosis patients in the scope of COVID-19. All patients with COVID-19 associated Mucormycosis (CAM) admitted to Assuit University Hospital between March 1, 2021, and July 30, 2021, were included in this study. The patient characteristics, the site of mucormycosis, the comorbidities, the steroids usage, and the outcome were analyzed in people with COVID-19.

Official Title
-----------------
COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital

Conditions
-----------------
Mucormycosis

Intervention / Treatment
-----------------
* Combination Product: antiviral, surgical


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:We recruited all cases admitted to Assuit University Hospital for the management of COVID-19 and/or associated complications between March 1, 2021, and July 30, 2021, specifically those with probable mucormycosis based on clinical condition. At various times, internists, intensivists, neurologists, and otolaryngologists were among the specialists who assessed and treated them. Clinical; radiological and histopathological confirmed cases of mucormycosis with coexisting or previous history of COVID-19 were included in this study. - Exclusion Criteria:Participants with fungal infections other than mucormycosis or without a confirmed diagnosis of COVID-19 (or serological evidence of preceding COVID-19) were excluded. -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| covid19<br>covid 19 proven by clinical, PCR. not associated with mucor | |
| covid19 associated with mucor<br>covid19 associated with mucor proven by clinical, histopathological | Combination Product: antiviral, surgical<br>* surgical debridment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of covid19 associated mucor |  | 3 months |
Treatment of Age-Related Macular Degeneration With Anecortave Acetate

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control classic neovascularization following failure of treatment with photodynamic therapy using Visudyne.

Official Title
-----------------
Treatment of Age-Related Macular Degeneration With Open-label Anecortave Acetate Sterile Suspension (15mg) Following Failed Treatment With Photodynamic Therapy With Visudyne

Conditions
-----------------
Macular Degeneration

Intervention / Treatment
-----------------
* Drug: Anecortave Acetate Sterile Suspension (15 mg)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of patients that previously had a failure of treatment with photodynamic therapy using Visudyne. Patients must be at least 50 years of age. Visual acuity of 20/30 to 20/320 in study eye on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart Visual acuity of 20/800 or better in fellow eye on the ETDRS visual acuity chart Exclusion Criteria: Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions. Patients who have undergone intraocular surgery within the last 2 months. Patient participating in any other investigational drug study. Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication. Inability to obtain photographs to document choroidal neovascularization (CNV) (including difficulty with venous access). Patient with significant liver disease or uremia. Patient with known adverse reaction to fluorescein and indocyanine green or iodine. Patient has a history of any medical condition which would preclude scheduled visits or completion of study Patient has had insertion of scleral buckle in the study eye Patient has received radiation treatment Patient is on anticoagulant therapy with the exception of aspirin Patient is pregnant or nursing.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Anecortave Acetate Sterile Suspension (15 mg)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Age-Related Macular Degeneration
A Novel Clinically Usable Point Score To Prejudge The Complexity Of Colonoscopy

Study Overview
=================
Brief Summary
-----------------
Colonoscopy is the current common method for management of colorectal diseases, and effectiveness of colonoscopy associate with complication rate. A lot of patients were failed because of technical difficulty, those required more than 10 min to intubate the cecum are consider as difficult colonoscopy, in such condition, specialized equipment or maneuvers may be required for a successful colonoscopy. Thus, it is important to set up a clinical model to predict the technical difficulty of the examination in preoperational stage.

Official Title
-----------------
A Novel Clinically Usable Point Score To Prejudge The Complexity Of Colonoscopy

Conditions
-----------------
Insertion Time

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients aged 18-90 years old who undergoing colonoscopy without sedation Exclusion Criteria: no bowel preparation or colon cleansing by enema only no need to reach cecum prior finding of severe colon stenosis or obstructing tumour history of colectomy unstable hemodynamics pregnant unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cecal intubation time | Total time of colonoscope intubation from anus to cecum. | up to 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
insertion time
Eye Movement Desensitization and Reprocessing (EMDR) in Non-specific Chronic Back Pain

Study Overview
=================
Brief Summary
-----------------
The study explores the feasibility of Eye-Movement-Desensitization and Reprocessing (EMDR) in non-specific chronic back pain.

Detailed Description
-----------------
The study explores the feasibility of Eye-Movement-Desensitization and Reprocessing (EMDR) in non-specific chronic back pain in a randomized controlled trial (RCT) with 6 months follow-up. The treatment consists of 12-sessions EMDR a 60 minutes using eye-movements for bilateral stimulation in addition to treatment as usual (TAU) that is compared to TAU alone.

Official Title
-----------------
Localized and Generalized Musculoskeletal Pain: Psychobiological Mechanisms and Implications for Treatment (LOGIN) - Subgroups Characterized by Psychological Trauma, Mental Comorbidity, and Psychobiological Patterns and Their Specialized Treatment - Eye Movement Desensitization and Reprocessing (EMDR) in Non-specific Chronic Back Pain

Conditions
-----------------
Non-specific Chronic Back Pain

Intervention / Treatment
-----------------
* Behavioral: Eye-Movement-Desensitization-Reprocessing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >= 18 years non-specific chronic low back pain >= 45 days/3 months high emotional distress caused by psychological trauma German language skills Exclusion Criteria: specific causes of chronic back pain application for retirement pension pending ongoing psychotherapy severe physical or psychiatric comorbidity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Eye-Movement-Desensitization-Reprocessing<br>Eye-Movement-Desensitization-Reprocessing | Behavioral: Eye-Movement-Desensitization-Reprocessing<br> <br> |
| No Intervention: Treatment as usual (control group)<br>treatment as usual | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in pain intensity | Numerical rating scale 0-10 | Change from Baseline Pain intensity at average 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Eye-Movement-Desensitization and Reprocessing, EMDR, Chronic back pain, treatment, CBP
Setting up a COVID-19 Care Facility at a Prison in Pakistan

Study Overview
=================
Brief Summary
-----------------
Presenting outline of the steps taken by our team to set up a Covid Care facility within the Prison setting. The facility was set up at Camp Jail (Lahore District Jail) located on Ferozpur Road, Lahore.

Detailed Description
-----------------
A prisoner brought to Camp Jail developed symptoms of and later tested positive for COVID-19. This lead to almost 527 contacts. An outbreak was expected. To manage the situation , a COVID-19 Care Facility was established within the prison. The study describes the steps taken by the team to set up this facility.

Official Title
-----------------
Setting up a COVID-19 Care Facility at a Prison in Pakistan

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Other: COVID-19 FACILITY


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - All COVID-19 positive prisoners within the Camp Jail Exclusion Criteria: Any patient being shifted to any other facility (except designated)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CASE<br>59 COVID-19 POSITIVE PRISONERS WHO UNDERWENT TREATMENT AT THE COVID-19 CARE FACILITY AT CAMP JAIL. | Other: COVID-19 FACILITY<br>* A COVID-19 facility was setup within the Prison. All positive prisoners were managed in the facility. If further intervention was required they were to be shifted to Services Hospital , Lahore.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recovery | Confirmed by double negative PCR results of specimen obtained via nasopharyngeal swabs | 30 days | 
| Mortality | Death of any of the patients who had tested positive at the Camp Jail | 30 days | 
| ICU admission | Any patient requiring admission to intensive care unit due to developing symptoms | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Prison, Pakistan
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

Study Overview
=================
Brief Summary
-----------------
Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.

Official Title
-----------------
A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus

Conditions
-----------------
Bacterial Pneumonia

Intervention / Treatment
-----------------
* Drug: Telavancin
* Drug: Vancomycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic care facility or acquired within 7 days after being discharged from a hospitalization of greater than or equal to 3 days duration. Exclusion Criteria: Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy for Gram-positive pneumonia immediately prior to randomization

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Telavancin<br> | Drug: Telavancin<br>* Telavancin 10 mg/kg/day IV for up to 21 days.<br>* Other names: VIBATIV;|
| Active Comparator: Vancomycin<br> | Drug: Vancomycin<br>* Vancomycin 1 Gm IV q 12 hrs for up to 21 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Response | Clinical Response: Categorical (Cured, Failed or Indeterminate) Failure is at least one of the following: Persistence or progression of signs and symptoms of pneumonia that still require antibiotic therapy; Termination of study med due to lack of efficacy; Death on or after Day 3 attributable to primary infection Cure: Signs and symptoms of pneumonia improved to the point that no further antibiotics for pneumonia were required, and baseline radiographic findings improved or did not progress. Indeterminate: Inability to determine outcome | 7 - 14 days following end of antibiotic treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nosocomial pneumonia, MRSA
ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes

Study Overview
=================
Brief Summary
-----------------
This study will be conducted to determine the pharmacodynamics, cardiovascular and biochemical effects of succinylcholine when given during electroconvulsive therapy. (ECT). This is a single center, prospective, study in patients who will be receiving ECT as indicated and prescribed by their psychiatrist. The study will be performed twice on each patient, 48-72 hours apart during consecutively scheduled ECT procedures.

Detailed Description
-----------------
Patients will receive the anesthetic that is traditionally given which includes appropriate doses of succinylcholine. Serum potassium and creatinine phosphokinase (CK) levels will be determined pre and post anesthesia; serum and urine myoglobin will be determined post anesthesia. Vital signs data [i.e., heart rate (arrhythmias) and arterial blood pressure] will be compared pre and post anesthesia. In addition patients will be asked about the presence of muscle pain (myalgia) 1 hour before discharge from the recovery room and the following day post ECT.

Official Title
-----------------
The Muscle Biochemical, Serum Potassium and Cardiovascular Changes After Succinylcholine in Patients Undergoing Electroconvulsive Therapy.

Conditions
-----------------
Depression

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A male or non-pregnant female aged 18 years and older American Society of Anesthesiologists physical status 1, 2, 3 Scheduled to undergo electroconvulsive therapy under general anesthesia Have given written informed consent Exclusion Criteria: Pregnant or nursing Any patient in the study investigators opinion who may not be suitable for research.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery

Study Overview
=================
Brief Summary
-----------------
This randomized controlled trial compares two regimens of topical therapy: tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day combination of tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day, plus Ketorolac tromethamine 0.5% (Acular®, Allergan), one drop three times/day. The topical treatment is administered for 28 days after phacoemulsification. Patients are independently assessed by two ophthalmologists. On day 28, patients are evaluated for corneal edema conjunctival redness anterior chamber reaction. Moreover, the cases necessitating continuation of treatment are compared in the two groups on day 28 and 42.

Official Title
-----------------
Tobramycin 0.3% - Dexamethasone 0.1% Versus Tobramycin 0.3% - Dexamethasone 0.1% Plus Ketorolac Tromethamine 0.5% After Phacoemulsification Surgery. A Randomized Trial

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Drug: Tobramycin 0.3% - Dexamethasone 0.1%
* Drug: Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Phacoemulsification (due to cataract) Uneventful phacoemulsification surgery Exclusion Criteria: Disruption of the anterior lens capsule Age-related macular degeneration Proliferative diabetic retinopathy Glaucoma

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Tobramycin 0.3% - Dexamethasone 0.1%<br> | Drug: Tobramycin 0.3% - Dexamethasone 0.1%<br> <br> |
| Active Comparator: Tobramycin-Dexamethasone plus Ketorolac tromethamine<br> | Drug: Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cataract, Phacoemulsification, Treatment duration
Articaine vs Dexmedetomidine Supplemented Articaine

Study Overview
=================
Brief Summary
-----------------
The aim of this study to test efficacy of adding dexmedetomidine to articaine on sensory, motor and duration of analgesia during hemodialysis fistula creation under ultrasound guided supraclavicular block

Detailed Description
-----------------
Adult fifty patient with chronic renal failure on hemodialysis, scheduled for arteriovenous fistula creation under ultrasound guided supraclavicular block. Patients were randomly allocated in two group. The articaine group (group A) received 40 ml articaine hydrochloride 2% and articaine-dexmedetomidine group (group AD) received 40 ml. Of articaine 2% mixed with dexmedetomidine (1micogram/kg)

Official Title
-----------------
Articaine and Dexmedetomidine - Supplemented Articaine for Arteriovenous Fistula Creation Under Ultrasound- Guided Supraclavicular Block

Conditions
-----------------
Renal Failure

Intervention / Treatment
-----------------
* Drug: Articaine
* Drug: Dexmedetomidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patient with chronic renal failure on hemodialysis scheduled for radiocephalic fistula creation Exclusion Criteria: Allergy to local anesthetics. Infection at the site of needle insertion. Those having international normalized ratio more than 1.5. Coagulopathy. Neuromuscular, or severe hepatic or severe pulmonary disease. Those having epilepsy. Patients who refused to participate.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group A<br>Patients received ultrasound guided supraclavicular block with 40 ml of Articaine hydrochloride 2% | Drug: Articaine<br>* Vial<br>|
| Experimental: Group AD<br>Patients received ultrasound guided supraclavicular block with 40 ml articaine 2% mixed with dexmedetomidine (1 µg/kg). | Drug: Articaine<br>* Vial<br>Drug: Dexmedetomidine<br>* Vial<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of sensory block | Sensory block time tested by pinprick test measured in minute | 24 hours | 
| Duration of motor block | Motor block time tested by Bromage scale measured in minutes | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of analgesia | Measured by visual analog scale score 4 | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemodialysis